Sana Biotechnology (SANA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual Meeting scheduled for June 4, 2026, will be held virtually via live audio webcast.
Proxy materials are available online, with paper copies available upon request by May 25, 2026.
Voting is accessible online using a 12-digit control number provided to shareholders.
Voting matters and shareholder proposals
Shareholders will vote to elect three Class II directors for three-year terms expiring at the 2029 annual meeting.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proxies may vote on any other business that may properly come before the meeting.
Board of directors and corporate governance
Nominees for election to the board are Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D.
Board recommends voting FOR each director nominee and FOR the auditor ratification proposal.
Latest events from Sana Biotechnology
- Virtual annual meeting to elect directors, ratify auditor, and review governance and compensation.SANA
Proxy filing24 Apr 2026 - Gene-edited cell therapies advance toward phase I trials, targeting scalable cures for type 1 diabetes.SANA
44th Annual J.P. Morgan Healthcare Conference15 Apr 2026 - Hypoimmune cell and in vivo CAR T therapies advance toward clinical milestones in 2026.SANA
Corporate presentation13 Apr 2026 - Hypoimmune and in vivo CAR T platforms advance toward clinical trials, with key data expected soon.SANA
The Citizens Life Sciences Conference 202611 Mar 2026 - Advanced clinical programs and improved financials with cash runway into late 2026.SANA
Q4 20253 Mar 2026 - Curative cell therapies for diabetes and in vivo CAR T-cells advance toward key clinical milestones.SANA
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Multiple clinical programs using hypoimmune technology expect pivotal data this year.SANA
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Promising cell therapy advances target diabetes, autoimmune, and cancer, with scale and funding as hurdles.SANA
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Promising cell therapy advances target diabetes, autoimmune, and cancer, with key data expected soon.SANA
2024 Wells Fargo Healthcare Conference22 Jan 2026